Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.
Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…Identifying delirium in Parkinson’s: evaluation of existing tools and measures
Objective: To evaluate the diagnostic accuracy of tools to identify delirium in inpatients with Parkinson’s disease (PD). Background: Delirium is a serious acute state of…Neuropsychiatric Symptoms in Early-Onset Parkinson’s Disease
Objective: To describe the neuropsychiatric symptoms of Early-Onset Parkinson’s Disease (EOPD) patients in an incident cohort study from 1991 to 2010 in Olmsted County, Minnesota…Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease
Objective: To determine the severity of various neuropsychiatric disturbances in drug-naïve Parkinson’s disease (PD) patients with (PD-OD) and without olfactory dysfunction (PD-NOD) compared to healthy…Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…Clinico-genetic analysis of patients with Parkinson’s disease and GBA mutations from a tertiary care teaching centre in India
Objective: To describe the clinico-genetic association of PD patients with heterozygous GBA mutations (PDwG). Background: Parkinson’s disease (PD) is currently understood to be the outcome…Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease
Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis
Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 14
- Next Page »